Mediar Therapeutics
Mediar Therapeutics develops precision therapies targeting fibrosis by focusing on myofibroblasts, the cells that drive scarring and organ failure. The Boston-based biotech has raised $181M and employs 57 people.
The growth story
Mediar Therapeutics grew from 22 to 57 employees between 2022 and 2026, raising $181M along the way, most recently a Series B in January 2026.
About
Mediar Therapeutics creates anti-fibrotic treatments that aim to stop disease progression by targeting myofibroblasts, the cells responsible for scarring and organ damage. Its approach combines novel targets with blood biomarkers and established treatment modalities to develop precision therapies.
The company has raised $181M in funding, including a Series B round in January 2026. Its investor base includes major pharmaceutical companies like Bristol-Myers Squibb and Eli Lilly, as well as venture capital firms like Amplitude Venture Capital.
Founders and leadership
Mediar's largest function is research, with 9 employees dedicated to this area. The company is led by a team with deep expertise in fibrosis and drug development, supported by investors with strong pharmaceutical industry ties.
The Mediar Therapeutics org chart
Rahul Ballal (CEO) leads 27 mapped leaders with 5 direct reports. Click +N to expand a team; names link to the person’s public profile.
Departments, and which ones grew
Headcount by function: Research 20 (+5% YoY), Business Development 14 (+8% YoY), Healthcare Services 4 (+100% YoY).
Talent flow
Mediar recruits heavily from Harvard Medical School and Pfizer, with 7 hires from each. Its workforce also includes former employees of Imara, Massachusetts General Hospital, and Agios Pharmaceuticals. Alumni have moved on to companies like Novartis, Bristol Myers Squibb, and Lytica Therapeutics.
Most common previous employers of Mediar Therapeutics staff: Harvard Medical School (7), Pfizer (7), Imara (5), Massachusetts General Hospital (4), Agios Pharmaceuticals (3), Agenus (2). Former Mediar Therapeutics employees most often moved to Novartis (2), Lytica Therapeutics (2), Bristol Myers Squibb (2), Violet Therapeutics (1), Valo Health (1), Affinity Asset Advisors (1).
Alumni worth knowing
Web traffic
Traffic mix: 0% direct, 0% search, 0% social, 0% paid.
What this company is made of
Most common skills at Mediar Therapeutics: Biotechnology (24), Life Sciences (19), Pharmaceutics (17), Biochemistry (17), Molecular Biology (17), Cell Culture (17), Cell Biology (16), Drug Development (16).
Where the team actually sits
Mediar Therapeutics people are concentrated in Massachusetts, United States (23), Greater Boston (9), United States (3), England, United Kingdom (1).
Search footprint
Mediar Therapeutics attracts about 47 organic search visits a month, traffic worth roughly $1K a month if bought through ads. It gained 33 ranking keywords and lost 14 in the last period.
Frequently asked
Mediar Therapeutics has 57 employees as of September 2026.
Mediar Therapeutics has raised $181M in total, most recently a Series B round in January 2026.
Mediar Therapeutics was founded in 2019 by David Lagares, PhD, MBA, Vishal Vaidya.
Rahul Ballal (CEO) sits at the top of Mediar Therapeutics's reporting structure, with 5 direct reports.
The most common previous employers of current Mediar Therapeutics staff are Harvard Medical School (7 people), Pfizer (7 people), Imara (5 people).
Former Mediar Therapeutics employees most often move to Novartis (2), Lytica Therapeutics (2), Bristol Myers Squibb (2).
Mediar Therapeutics attracts about 47 organic search visits a month, worth roughly $1K a month in equivalent ad spend.
The most common skills among Mediar Therapeutics staff are Biotechnology, Life Sciences, Pharmaceutics, Biochemistry, Molecular Biology.
Mediar Therapeutics staff are concentrated in Massachusetts, United States (23), Greater Boston (9), United States (3).
Mediar Therapeutics has about 20 people in Research, up 5% over the past year, as of September 2026.
Mediar Therapeutics has about 14 people in Business Development, up 8% over the past year, as of September 2026.
Computed from 43 current and 32 former Mediar Therapeutics profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.